Lamichhane Tek N, Sokic Sonja, Schardt John S, Raiker Rahul S, Lin Jennifer W, Jay Steven M
1 Fischell Department of Bioengineering, University of Maryland , College Park, Maryland.
Tissue Eng Part B Rev. 2015 Feb;21(1):45-54. doi: 10.1089/ten.TEB.2014.0300. Epub 2014 Jul 24.
Extracellular vesicles (EVs)-comprising a heterogeneous population of cell-derived lipid vesicles including exosomes, microvesicles, and others-have recently emerged as both mediators of intercellular information transfer in numerous biological systems and vehicles for drug delivery. In both roles, EVs have immense potential to impact tissue engineering and regenerative medicine applications. For example, the therapeutic effects of several progenitor and stem cell-based therapies have been attributed primarily to EVs secreted by these cells, and EVs have been recently reported to play direct roles in injury-induced tissue regeneration processes in multiple physiological systems. In addition, EVs have been utilized for targeted drug delivery in regenerative applications and possess unique potential to be harnessed as patient-derived drug delivery vehicles for personalized medicine. This review discusses EVs in the context of tissue repair and regeneration, including their utilization as drug carriers and their crucial role in cell-based therapies. Furthermore, the article highlights the growing need for bioengineers to understand, consider, and ultimately design and specifically control the activity of EVs to maximize the efficacy of tissue engineering and regenerative therapies.
细胞外囊泡(EVs)——包括由细胞衍生的脂质囊泡组成的异质群体,如外泌体、微囊泡等——最近已成为众多生物系统中细胞间信息传递的介质以及药物递送的载体。在这两种作用中,EVs对组织工程和再生医学应用都具有巨大的影响潜力。例如,几种基于祖细胞和干细胞的疗法的治疗效果主要归因于这些细胞分泌的EVs,并且最近有报道称EVs在多个生理系统的损伤诱导组织再生过程中发挥直接作用。此外,EVs已被用于再生应用中的靶向药物递送,并具有作为患者来源的药物递送载体用于个性化医疗的独特潜力。本综述在组织修复和再生的背景下讨论了EVs,包括它们作为药物载体的用途及其在基于细胞的疗法中的关键作用。此外,本文强调了生物工程师越来越需要理解、考虑并最终设计和特异性控制EVs的活性,以最大限度地提高组织工程和再生疗法的疗效。